Deriving Drug Discovery Value from Large-Scale Genetic Bioresources

- Proceedings of a Workshop

af


Deriving Drug Discovery Value from Large-Scale Genetic Bioresources
Du sparer Spar kr. 59,60 med Shopping-fordele
  • Leveringstid 5-10 hverdage
  • Forventet levering 06-05-2021
For at købe bogen til fordelspris skal du have et medlemskab med Shopping-fordele. Du kan prøve medlemskabet gratis de første 30 dage. Medlemskabet fornyes automatisk og kan altid opsiges. Læs mere om medlemskaber og Shopping-fordele her.
Format:
Bog, paperback
Udgivelsesdato:
02-12-2016
Sprog:
Engelsk
Sidetal:
114
  • Beskrivelse
  • Yderligere info
  • Anmeldelser

The process of discovering and developing a new drug or therapy is extremely costly and time consuming, and recently, it has been estimated that the creation of a new medicine costs on average more than $2 billion and takes 10 years to reach patients. The challenges associated with bringing new medicines to market have led many pharmaceutical companies to seek out innovative methods for streamlining their drug discovery research.One way to increase the odds of success for compounds in the drug development pipeline is to adopt genetically guided strategies for drug discovery, and recognizing the potential benefits of collecting genetic and phenotypic information across specific populations, pharmaceutical companies have started collaborating with healthcare systems and private companies that have curated genetic bioresources, or large databases of genomic information. Large-scale cohort studies offer an effective way to collect and store information that can be used to assess geneaEURO"environment interactions, identify new potential drug targets, understand the role of certain genetic variants in the drug response, and further elucidate the underlying mechanisms of disease onset and progression.To examine how genetic bioresources could be used to improve drug discovery and target validation, the National Academies of Sciences, Engineering, and Medicine hosted a workshop in March 2016. Participants at the workshop explored the current landscape of genomics-enabled drug discovery activities in industry, academia, and government; examined enabling partnerships and business models; and considered gaps and best practices for collecting population data for the purpose of improving the drug discovery process. This publication summarizes the presentations and discussions from the workshop.

Andre udgaver:

E-bog, ePub
E-bog, PDF

Vis mereVis mindre

Udgivelsesdato:
02-12-2016
ISBN13:
9780309447782
Bredde:
152 mm
Højde:
229 mm
Format:
Paperback
Bibliotekernes beskrivelse The process of discovering and developing a new drug or therapy is extremely costly and time consuming, and recently, it has been estimated that the creation of a new medicine costs on average more than $2 billion and takes 10 years to reach patients. The challenges associated with bringing new medicines to market have led many pharmaceutical companies to seek out innovative methods for streamlining their drug discovery research. One way to increase the odds of success for compounds in the drug development pipeline is to adopt genetically guided strategies for drug discovery, and recognizing the potential benefits of collecting genetic and phenotypic information across specific populations, pharmaceutical companies have started collaborating with healthcare systems and private companies that have curated genetic bioresources, or large databases of genomic information.Large-scale cohort studies offer an effective way to collect and store information that can be used to assess genea "environment interactions, identify new potential drug targets, understand the role of certain genetic variants in the drug response, and further elucidate the underlying mechanisms of disease onset and progression. To examine how genetic bioresources could be used to improve drug discovery and target validation, the National Academies of Sciences, Engineering, and Medicine hosted a workshop in March 2016. Participants at the workshop explored the current landscape of genomics-enabled drug discovery activities in industry, academia, and government; examined enabling partnerships and business models; and considered gaps and best practices for collecting population data for the purpose of improving the drug discovery process. This publication summarizes the presentations and discussions from the workshop.

Vis mereVis mindre

Vis mereVis mindre

Fandt du ikke hvad du søgte?

Hvis denne bog ikke er noget for dig, kan du benytte kategorierne nedenfor til at finde andre titler. Klik på en kategori for at se lignende bøger.

Velkommen til Saxo – din danske boghandel!

Hos os kan du handle som gæst, Saxo-bruger eller Premium-medlem – du bestemmer helt selv. Skulle du få brug for hjælp, sidder vores kundeservice-team klar ved både telefonerne og tasterne.

Om fordelspriser hos Saxo

For at købe bøger til fordelspris, skal du være medlem af Premium, Premium Shopping eller Premium Studie. De første 30 dage er gratis for nye medlemmer. Medlemskabet fornyes automatisk og kan altid opsiges. Læs mere om fordelene ved vores forskellige medlemskaber her.

Machine Name: SAXO081